Changes in breast density and circulating estrogens in postmenopausal women receiving adjuvant anastrozole.

ABSTRACT: Factors associated with an increased risk of breast cancer include prior breast cancer, high circulating estrogens, and increased breast density. Adjuvant aromatase inhibitors are associated with a reduction in incidence of contralateral breast cancer. We conducted a prospective, single-arm, single-institution study to determine whether use of anastrozole is associated with changes in contralateral breast density and circulating estrogens. Eligible patients included postmenopausal women with hormone receptor-positive early-stage breast cancer who had completed local therapy, had an intact contralateral breast, and were recommended an aromatase inhibitor as their only systemic therapy. Participants received anastrozole 1 mg daily for 12 months on study. We assessed contralateral breast dens

SUBMITTER: Prowell TM 

PROVIDER: S-EPMC3700336 | biostudies-literature | 2011 Dec

REPOSITORIES: biostudies-literature